Home » Transition in New Licensing Deal with Eli Lilly
Transition in New Licensing Deal with Eli Lilly
Canadian Transition Therapeutics has made a deal with Eli Lilly to license the latter’s TT-601 small molecule transcription regulator to treat osteoarthritis pain.
The Pharma Letter
The Pharma Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May